The Polymerase L528M Mutation Cooperates with Nucleotide Binding-site Mutations, Increasing Hepatitis B Virus Replication and Drug Resistance

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2001 Feb 22

PMID 11181644

Citations 76

Authors

S K Ono

N Kato

Y Shiratori

J Kato

T Goto

R F Schinazi

F J Carrilho

M Omata

Affiliations

Soon will be listed here.

Abstract

After receiving lamivudine for 3 years to treat chronic hepatitis B, 67-75% of patients develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase that render hepatitis B virus (HBV) drug-resistant. The aim of this study was to evaluate the influence of these mutations on viral replication and resistance to antiviral agents. We investigated the replication fitness and susceptibility of the wild-type and five mutant HBVs (L528M, M552I, M552V, L528M/M552I, and L528M/M552V) to 11 compounds [lamivudine, adefovir, entecavir (BMS-200475) (+)-BCH-189 (+/-)-FTC (racivir) (-)-FTC (emtricitabine) (+)-FTC, L-D4FC, L-FMAU (clevudine), D-DAPD, and (-)-carbovir] by transfecting HBV DNA into hepatoma cells and monitoring viral products by Southern blotting. The replication competency of the single C-domain mutants M552I and M552V was markedly decreased compared with that of wild-type HBV. However, addition of the B-domain mutation L528M restored replication competence. Only adefovir and entecavir were effective against all five HBV mutants, and higher doses of these compounds were necessary to inhibit the double mutants compared with the single mutants. The B-domain mutation (L528M) of HBV polymerase not only restores the replication competence of C-domain mutants, but also increases resistance to nucleoside analogues.

Citing Articles

Hepatitis B x antigen (HBx) is an important therapeutic target in the pathogenesis of hepatocellular carcinoma.

Medhat A, Arzumanyan A, Feitelson M Oncotarget. 2021; 12(24):2421-2433.

PMID: 34853663 PMC: 8629409. DOI: 10.18632/oncotarget.28077.

Moving Fast Toward Hepatitis B Virus Elimination.

Bassit L, Ono S, Schinazi R Adv Exp Med Biol. 2021; 1322:115-138.

PMID: 34258739 PMC: 8988908. DOI: 10.1007/978-981-16-0267-2_5.

Regulation Between HSF1 Isoforms and HSPs Contributes to the Variation in Thermal Tolerance Between Two Oyster Congeners.

Liu Y, Li L, Qi H, Que H, Wang W, Zhang G Front Genet. 2020; 11:581725.

PMID: 33193707 PMC: 7652795. DOI: 10.3389/fgene.2020.581725.

Coevolution analysis of amino-acids reveals diversified drug-resistance solutions in viral sequences: a case study of hepatitis B virus.

Teppa E, Nadalin F, Combet C, Zea D, David L, Carbone A Virus Evol. 2020; 6(1):veaa006.

PMID: 32158552 PMC: 7050494. DOI: 10.1093/ve/veaa006.

Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study.

Abreu R, Bassit L, Tao S, Jiang Y, Ferreira A, Hori P Antivir Ther. 2019; 24(8):567-579.

PMID: 31799942 PMC: 7722940. DOI: 10.3851/IMP3338.

References

Benhamou Y, BOCHET M, Thibault V, Di Martino V, Caumes E, Bricaire F . Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999; 30(5):1302-6. DOI: 10.1002/hep.510300525. View

Ben-Ari Z, Pappo O, Zemel R, Mor E, Tur-Kaspa R . Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis. Transplantation. 1999; 68(2):232-6. DOI: 10.1097/00007890-199907270-00012. View

Korba B, Schinazi R, Cote P, Tennant B, Gerin J . Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother. 2000; 44(6):1757-60. PMC: 89954. DOI: 10.1128/AAC.44.6.1757-1760.2000. View

Yeh C, Chien R, Chu C, Liaw Y . Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology. 2000; 31(6):1318-26. DOI: 10.1053/jhep.2000.7296. View

Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J . Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982; 42(9):3858-63. View

Kamer G, Argos P . Primary structural comparison of RNA-dependent polymerases from plant, animal and bacterial viruses. Nucleic Acids Res. 1984; 12(18):7269-82. PMC: 320156. DOI: 10.1093/nar/12.18.7269. View

Yokosuka O, Omata M, Imazeki F, Okuda K, Summers J . Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: analysis of intrahepatic replicative hepatitis B virus DNA. Hepatology. 1985; 5(5):728-34. DOI: 10.1002/hep.1840050505. View

Sells M, Chen M, Acs G . Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1987; 84(4):1005-9. PMC: 304350. DOI: 10.1073/pnas.84.4.1005. View

Poch O, Sauvaget I, Delarue M, Tordo N . Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J. 1989; 8(12):3867-74. PMC: 402075. DOI: 10.1002/j.1460-2075.1989.tb08565.x. View

10.

Furman P, Davis M, Liotta D, Paff M, Frick L, Nelson D . The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992; 36(12):2686-92. PMC: 245529. DOI: 10.1128/AAC.36.12.2686. View

11.

Jansen R, Johnson L, Averett D . High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chemother. 1993; 37(3):441-7. PMC: 187690. DOI: 10.1128/AAC.37.3.441. View

12.

Ding J, Nanni R, Clark Jr A, Lu X, Tantillo C, Williams R . Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A. 1993; 90(13):6320-4. PMC: 46920. DOI: 10.1073/pnas.90.13.6320. View

13.

Heijtink R, de Wilde G, Kruining J, Berk L, Balzarini J, De Clercq E . Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res. 1993; 21(2):141-53. DOI: 10.1016/0166-3542(93)90050-s. View

14.

Coffin J . HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995; 267(5197):483-9. DOI: 10.1126/science.7824947. View

15.

Kruining J, Heijtink R, Schalm S . Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. J Hepatol. 1995; 22(3):263-7. DOI: 10.1016/0168-8278(95)80277-0. View

16.

Gunther S, Li B, Miska S, Kruger D, Meisel H, Will H . A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol. 1995; 69(9):5437-44. PMC: 189390. DOI: 10.1128/JVI.69.9.5437-5444.1995. View

17.

Havlir D, Richman D . Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med. 1996; 124(11):984-94. DOI: 10.7326/0003-4819-124-11-199606010-00006. View

18.

Ling R, Mutimer D, Ahmed M, Boxall E, Elias E, Dusheiko G . Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 1996; 24(3):711-3. DOI: 10.1002/hep.510240339. View

19.

Tipples G, Ma M, Fischer K, Bain V, Kneteman N, Tyrrell D . Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 1996; 24(3):714-7. DOI: 10.1002/hep.510240340. View

20.

Pai S, Liu S, Zhu Y, Chu C, Cheng Y . Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother. 1996; 40(2):380-6. PMC: 163120. DOI: 10.1128/AAC.40.2.380. View